Opdivo plus Yervoy approved for mCRC

Bristol-Myers Squibb Co. (NYSE:BMY) said FDA granted accelerated approval to Opdivo nivolumab plus Yervoy ipilimumab

Read the full 154 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE